CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDI CALIDI BIOTHERAPEUTICS INC

Closed 04-21 16:00:00 EDT

0.2218

-0.0284

-11.35%

盘后0.2377

+0.0159+7.17%

19:59 EDT

High0.2916	Low0.2146	Vol13.13M
Open0.2473	D1 Closing0.2502	Amplitude30.78%
Mkt Cap2.42M	Tradable Cap2.16M	Total Shares10.90M
T/O3.36M	T/O Rate134.65%	Tradable Shares9.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":0.2218,"timestamp":1776801600000,"preClose":0.2502,"halted":0,"volume":13133574,"hourTrading":{"tag":"盘后","latestPrice":0.2377,"preClose":0.2218,"latestTime":"19:59 EDT","volume":935279,"amount":216562.432928,"timestamp":1776815957910,"change":0.0159,"changeRate":0.071686,"amplitude":0.112714},"delay":0,"changeRate":-0.11350919264588323,"floatShares":9753500,"shares":10895725,"eps":-5.95,"marketStatus":"Closed","change":-0.0284,"latestTime":"04-21 16:00:00 EDT","open":0.2473,"high":0.2916,"low":0.2146,"amount":3362642.7988734,"amplitude":0.307754,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-5.95,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776844800000},"marketStatusCode":5,"adr":0,"exchange":"AMEX","adjPreClose":0.2502,"preHourTrading":{"tag":"盘前","latestPrice":0.2499,"preClose":0.2502,"latestTime":"09:24 EDT","volume":41425,"amount":10315.64231525,"timestamp":1776777878702,"change":-0.0003,"changeRate":-0.001199,"amplitude":0.059552},"postHourTrading":{"tag":"盘后","latestPrice":0.2377,"preClose":0.2218,"latestTime":"19:59 EDT","volume":935279,"amount":216562.432928,"timestamp":1776815957910,"change":0.0159,"changeRate":0.071686,"amplitude":0.112714},"volumeRatio":4.753272},"requestUrl":"/m/hq/s/CLDI","defaultTab":"news","newsList":[{"id":"2629032074","title":"Calidi presents new data on CLD-401 at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2629032074","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629032074?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:29","pubTimestamp":1776778188,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) Biotherapeutics will present new data at the American Association of Cancer Research, AACR, annual meeting in San Diego, California o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-presents-new-data-on-cld-401-at-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-presents-new-data-on-cld-401-at-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628472535","title":"Calidi presents new data on in situ t-cell engagers at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2628472535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628472535?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:54","pubTimestamp":1776689678,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) Biotherapeutics presented new data at the American Association of Cancer Research, AACR, annual meeting in San Diego, California on A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-presents-new-data-on-in-situ-t-cell-engagers-at-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-presents-new-data-on-in-situ-t-cell-engagers-at-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628174003","title":"Calidi presents preclinical data for RedTail-derived CLD-401, targets IND filing end-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2628174003","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628174003?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:07","pubTimestamp":1776686825,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics presented new preclinical data on April 19, 2026 at AACR on its RedTail platform designed to drive tumor-restricted expression of immune-activating payloads.Results showed RedTail constructs could support simultaneous T-cell activation and in-tumor production of a T-cell engager, an approach aimed at improving activity in solid tumors while limiting peripheral exposure.Calidi highlighted CLD-401 as lead RedTail candidate, positioning it to remodel tumor microenvironment and support localized immune activation.Company also advanced CLD-501, a TROP2-targeting in situ T-cell engager program intended to reduce off-tumor risk tied to that antigen.Calidi expects to file an IND for CLD-401 by end of 2026, setting up a potential clinical entry point for RedTail.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL3b26wS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4112","CLDI","BK4139","SG9999014005.SGD","IE00BN0W2W23.USD","BK4585","LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","IE00BN0W2V16.EUR","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628798624","title":"Calidi Biotherapeutics publishes RedTail virotherapy platform presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2628798624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628798624?lang=en_us&edition=fundamental","pubTime":"2026-04-20 01:26","pubTimestamp":1776619587,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics published a research presentation outlining its RedTail dual-programmable virotherapy platform for systemic tumor targeting and localized gene delivery.RedTail uses a tumor-selective replicating extracellular enveloped vaccinia virus engineered with a chimeric CD55 to improve resistance to complement and neutralizing antibodies, supporting IV administration.Program updates highlighted CLD-401, designed for tumor-localized expression of an IL-15 superagonist, with preclinical data showing preferential tumor amplification with low off-tumor signal.Calidi also described CLD-501 as a next-generation construct intended to co-express an IL-15 superagonist with tumor-targeting bispecific T-cell engagers for localized activity in solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nNDL6jKvGd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628782724","title":"Calidi Biotherapeutics announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2628782724","media":"Reuters","labels":["shareholding","conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628782724?lang=en_us&edition=fundamental","pubTime":"2026-04-18 05:26","pubTimestamp":1776461162,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics scheduled virtual annual shareholder meeting for June 12, 2026.Shareholders set to vote on election of Class III director nominee Scott Leftwich to serve until 2029 annual meeting.Ballot includes auditor ratification for CBIZ CPAs P.C. for fiscal 2026.Investors to consider reverse stock split ratio range of 1-for-2 to 1-for-16.Meeting agenda also includes amendment to 2023 Equity Incentive Plan to raise share authorization to 1,950,000, plus potential adjournment to solicit additional votes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDLknnXH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627439445","title":"Calidi Biotherapeutics to present RedTail platform data at oncolytic virus conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627439445","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627439445?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:07","pubTimestamp":1776168429,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics to present at International Oncolytic Virus Conference in Reykjavik, Iceland on April 28, 2026.Presentation to highlight RedTail platform data, including lead candidate CLD-401.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLb5QyBm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4112","CLDI","BK4139","SG9999014005.SGD","IE00BN0W2W23.USD","BK4585","LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","IE00BN0W2V16.EUR","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625952768","title":"Calidi Biotherapeutics to present RedTail systemic virotherapy data at ASGCT meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2625952768","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625952768?lang=en_us&edition=fundamental","pubTime":"2026-04-08 00:29","pubTimestamp":1775579352,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics will present new preclinical data on its RedTail systemically delivered virotherapy platform at ASGCT annual meeting in Boston on May 14, 2026.Presentation is set to highlight RedTail EEV’s ability to evade immune clearance, replicate in target cells, and deliver genetic payloads to distal tumor sites.Update will include CLD-401, RedTail lead candidate engineered to express IL-15 superagonist in tumor microenvironment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL9MLNWy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","BK4585","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","SG9999014013.SGD","NDAQ","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","CLDI","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU2095319765.USD","BK4139","IE00BN0W2T93.GBP","BK4112","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624687167","title":"Calidi Biotherapeutics director Allan Camaisa to leave board at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2624687167","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624687167?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:01","pubTimestamp":1775163711,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics director Allan J. Camaisa plans to let his board term expire at 2026 annual stockholder meeting.Board size will shrink to five directors from six, effective at 2026 annual stockholder meeting.Scott Leftwich, Class III director, joined audit committee effective April 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3vK5b6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506960","title":"Calidi Biotherapeutics to present new CLD-401 preclinical data at AACR meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506960","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506960?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:03","pubTimestamp":1775131383,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics plans to present new preclinical data on lead oncology candidate CLD-401 at AACR annual meeting in San Diego on April 17-22, 2026.Presentation will cover tumor-restricted expression of IL-15 superagonist from systemically delivered oncolytic virus, intended to activate immune response in tumor microenvironment.Company expects data to support a therapeutic effect while limiting systemic cytokine exposure, which could improve tolerability profile.CLD-401 remains in IND-enabling studies, with IND filing targeted by end of 2026 and first clinical entry planned shortly afterward.Calidi also flagged ongoing efforts to pursue strategic partnerships to accelerate clinical development of RedTail platform.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL2zMQ5h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014021.USD","NDAQ","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","CLDI","BK4585","LU2210149790.SGD","BK4588","LU2095319765.USD","LU0314104364.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4139","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4112","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624151351","title":"Calidi Biotherapeutics to present AACR data on RedTail TROP-2 T-cell engager candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2624151351","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624151351?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:03","pubTimestamp":1775045020,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics will present new preclinical data at AACR annual meeting in San Diego on April 17-22, 2026 on its RedTail virotherapy approach to in situ T-cell engagers.Presentation will highlight RedTail viruses designed to activate T-cells in tumors while driving local production of a T-cell engager, aiming to improve activity in solid tumors.Calidi is advancing a new RedTail-derived candidate targeting TROP-2, positioning tumor-restricted expression as a way to reduce off-tumor toxicity risk seen with systemic T-cell engagers.Lead RedTail program CLD-401 remains on track for an IND filing by end of 2026, supporting broader platform validation ahead of clinical entry.Company is pursuing strategic partnerships to accelerate clinical development of RedTail-based programs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL5Zhpz8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4585","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014013.SGD","LU2210150020.SGD","BK4588","LU2210149790.SGD","NDAQ","SG9999014005.SGD","BK4139","BK4112","SG9999014021.USD","CLDI","LU0314104364.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808985","title":"Calidi Biotherapeutics FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808985","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808985?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:25","pubTimestamp":1774643151,"startTime":"0","endTime":"0","summary":"Calidi published a press release reporting fourth-quarter and full-year 2025 financial results and recent operational updates.Net loss attributable to common stockholders was USD 4.1 million for Q4, or USD 0.57 per share.R&D expense rose 33.33% to USD 2.4 million in Q4, while G&A expense fell 4.55% to USD 2.1 million.Net loss attributable to common stockholders was USD 25.6 million for FY 2025, or USD 5.95 per share.Cash was USD 5.6 million at Dec. 31, 2025, and the company said it expects to file an IND for CLD-401 by end of 2026 after FDA Type D interactions and partnerships with Avance Clinical and Matica Bio.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8W50W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","CLDI","LU0314104364.USD","BK4139","LU2095319765.USD","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622089578","title":"Calidi Biotherapeutics Inc: Q4 Net Loss per Share $0.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2622089578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622089578?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:25","pubTimestamp":1774643133,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nTUA4XNBYG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808987","title":"Press Release: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808987?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:25","pubTimestamp":1774643100,"startTime":"0","endTime":"0","summary":"-- Announced partnership with Australian CRO to accelerate initiation of. -- The Company has received feedback from the FDA through Type D. interactions, and the Company believes its manufacturing and analytical. approaches for CLD-401 are in alignment with FDA guidance; Calidi expects. -- Partnered with Matica Bio around the GMP manufacturing of CLD-401. -- Presented new data on in situ T-cell engagers  at 2026 AACR-IO. SAN DIEGO, March 27, 2026  -- Calidi Biotherapeutics Inc.  , a biotechnology company pioneering the development of targeted genetic medicines, today reported its fourth quarter and full-year 2025 operating and financial results and reviewed recent business highlights.\"We are extremely excited about the continued progress at Calidi,\" said Eric Poma, PhD, CEO of Calidi Biotherapeutics. \"We continue to advance CLD-401, the first lead from our RedTail platform, towards the clinic and have built a world-class scientific advisory board to aid those efforts. We have also expa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621106425","title":"BRIEF-Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2621106425","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621106425?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:18","pubTimestamp":1774354706,"startTime":"0","endTime":"0","summary":"BRIEF-Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory ApprovalMarch 24 (Reuters) - Calidi Biotherapeutics Inc CLDI.A:CALIDI BIOTHERAPEUTICS ANNOUN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C09V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064472","title":"Calidi Biotherapeutics Announces Partnership With Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of Cld-401 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064472?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:16","pubTimestamp":1774354598,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C09V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064600","title":"Calidi Biotherapeutics partners with Avance Clinical on CLD-401 trial launch in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064600","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064600?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:04","pubTimestamp":1774353885,"startTime":"0","endTime":"0","summary":"Calidi partnered with Avance Clinical to support Australian regulatory approval and accelerate initiation of first-in-human clinical trials for CLD-401 in Australia.The collaboration is intended to facilitate clinical trial initiation in Australia while Calidi pursues an FDA IND filing in 2026.CLD-401 is a genetically modified vaccinia virus designed to replicate only in tumor cells and express an IL-15 superagonist in the tumor microenvironment.The planned phase I trial will evaluate safety and pharmacodynamics in patients with solid tumors.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL7fnRVd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4585","BK4139","IE00BKPKM429.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014005.SGD","NDAQ","LU0314104364.USD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","CLDI","IE00B64PRP62.GBP","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618134673","title":"Calidi Biotherapeutics presents CLD-401 manufacturing process at BioProcessing Summit in Barcelona","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134673","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134673?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:03","pubTimestamp":1773316990,"startTime":"0","endTime":"0","summary":"Calidi presented its manufacturing process for CLD-401 at the 9th Annual Bioprocessing Summit in Barcelona. The company said it has received FDA feedback through a Type D meeting request process related to its manufacturing and analytical approaches for CLD-401. Antonio Santidrian and Eric Poma spoke about the manufacturing strategy and regulatory interactions during the event.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL2FDp2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BKPKM429.USD","BK4139","CLDI","SG9999014005.SGD","BK4112","IE00B64PRP62.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","SG9999014039.USD","SG9999014013.SGD","SG9999014021.USD","LU0314104364.USD","BK4585","BK4588","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618411976","title":"Calidi Biotherapeutics announces proposed underwritten public offering of stock and warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2618411976","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618411976?lang=en_us&edition=fundamental","pubTime":"2026-03-12 05:12","pubTimestamp":1773263543,"startTime":"0","endTime":"0","summary":"Calidi said it plans an underwritten public offering of units consisting of common stock and, for certain investors, pre-funded warrants in lieu of common stock. Each unit will include accompanying common warrants to purchase common stock, and the securities will separate immediately upon issuance. The pre-funded warrants will be priced at the public offering price minus USD 0.001 per share, with an exercise price of USD 0.001 per share. Calidi expects to grant the underwriters a 45-day option to buy up to an additional 15% of the shares and/or common warrants offered. Ladenburg Thalmann is acting as sole book-running manager, and Calidi said it intends to use net proceeds for working capital and general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL8zKJLP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK4139","CLDI","LTSAP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618060623","title":"Press Release: Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2618060623","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618060623?lang=en_us&edition=fundamental","pubTime":"2026-03-10 08:50","pubTimestamp":1773103800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 09, 2026  -- Calidi Biotherapeutics, Inc.  , a biotechnology company pioneering the development of targeted genetic medicines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' over-allotment option for gross proceeds of approximately $6.0 million, prior to deducting underwriting commissions and offering expenses.In connection with the offering, the Company sold 12,094,631 shares of common stock  Series J warrants to purchase 12,094,631 shares of common stock, Series K warrants to purchase 12,094,631 shares of common stock, and Series L warrants to purchase 12,094,631 shares of common stock, including the full exercise of the underwriter's option to purchase 1,575,000 shares of common stock and accompanying warrants..Ladenburg Thalmann & Co. Inc. acted as sole book-running manager for the offering.This press release does not constitute an offer to sell or the solicitation of an offer to bu","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617263825","title":"BRIEF-Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2617263825","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617263825?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:34","pubTimestamp":1772804052,"startTime":"0","endTime":"0","summary":"BRIEF-Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public OfferingMarch 6 (Reuters) - Calidi Biotherapeutics Inc CLDI.A:CALIDI BIOTHERAPEUTICS ANNOUNCES PRICING OF $5.2 MILLIO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA92TXCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.calidibio.com","stockEarnings":[{"period":"1week","weight":-0.1112},{"period":"1month","weight":-0.1159},{"period":"3month","weight":-0.7523},{"period":"6month","weight":-0.8263},{"period":"1year","weight":-0.955},{"period":"ytd","weight":-0.7862}],"compareEarnings":[{"period":"1week","weight":0.033},{"period":"1month","weight":0.0927},{"period":"3month","weight":0.046},{"period":"6month","weight":0.0613},{"period":"1year","weight":0.3463},{"period":"ytd","weight":0.0393}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.185839},{"month":2,"riseRate":0.6,"avgChangeRate":-0.062337},{"month":3,"riseRate":0.4,"avgChangeRate":-0.220856},{"month":4,"riseRate":0.4,"avgChangeRate":-0.150587},{"month":5,"riseRate":0.25,"avgChangeRate":-0.071752},{"month":6,"riseRate":0.75,"avgChangeRate":-0.069766},{"month":7,"riseRate":0.75,"avgChangeRate":0.345315},{"month":8,"riseRate":0.25,"avgChangeRate":-0.291823},{"month":9,"riseRate":0,"avgChangeRate":-0.182897},{"month":10,"riseRate":0.75,"avgChangeRate":-0.07151},{"month":11,"riseRate":0.5,"avgChangeRate":0.188661},{"month":12,"riseRate":0.2,"avgChangeRate":-0.191351}],"exchange":"AMEX","name":"CALIDI BIOTHERAPEUTICS INC","nameEN":"CALIDI BIOTHERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CALIDI BIOTHERAPEUTICS INC,CLDI,CALIDI BIOTHERAPEUTICS INC股票,CALIDI BIOTHERAPEUTICS INC股票老虎,CALIDI BIOTHERAPEUTICS INC股票老虎国际,CALIDI BIOTHERAPEUTICS INC行情,CALIDI BIOTHERAPEUTICS INC股票行情,CALIDI BIOTHERAPEUTICS INC股价,CALIDI BIOTHERAPEUTICS INC股市,CALIDI BIOTHERAPEUTICS INC股票价格,CALIDI BIOTHERAPEUTICS INC股票交易,CALIDI BIOTHERAPEUTICS INC股票购买,CALIDI BIOTHERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}